Financials ASKA Pharmaceutical Holdings Co.,Ltd.

Equities

4886

JP3119660003

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 16/05/2024 BST			5-day change	1st Jan Change
2,302 ^JPY	-1.67%		+8.74%	+29.04%

2023	Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	CI
2023	ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Valuation

Fiscal Period: March	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	32,362	31,095	44,958	35,672	33,620	65,214	-	-
Enterprise Value (EV) ¹	37,848	40,220	50,839	32,615	28,338	62,863	52,906	48,024
P/E ratio	18.5 x	47.8 x	15.4 x	8.35 x	7.92 x	8.33 x	12.7 x	12.2 x
Yield	1.22%	1.55%	0.95%	1.19%	1.35%	1.8%	2.17%	2.1%
Capitalization / Revenue	0.69 x	0.59 x	0.81 x	0.63 x	0.56 x	1 x	1.01 x	0.97 x
EV / Revenue	0.81 x	0.77 x	0.92 x	0.58 x	0.47 x	1 x	0.82 x	0.72 x
EV / EBITDA	8.86 x	7.63 x	7.35 x	2.39 x	3.44 x	5.44 x	5.57 x	4.98 x
EV / FCF	246 x	-15.8 x	9.35 x	14.9 x	13.7 x	16.4 x	9.58 x	13.2 x
FCF Yield	0.41%	-6.34%	10.7%	6.7%	7.32%	6.1%	10.4%	7.6%
Price to Book	0.74 x	0.75 x	0.94 x	0.73 x	0.62 x	1.02 x	1.01 x	0.94 x
Nbr of stocks (in thousands)	28,239	28,320	30,563	28,243	28,276	28,329	-	-
Reference price ²	1,146	1,098	1,471	1,263	1,189	2,302	2,302	2,302
Announcement Date	10/05/19	12/05/20	11/05/21	12/05/22	11/05/23	10/05/24	-	-

¹JPY in Million²JPY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	46,706	52,542	55,181	56,607	60,461	62,843	64,484	66,980
EBITDA ¹	4,273	5,268	6,915	13,633	8,235	8,984	9,500	9,642
EBIT ¹	1,782	1,507	3,609	4,795	5,108	6,500	6,713	6,929
Operating Margin	3.82%	2.87%	6.54%	8.47%	8.45%	10.34%	10.41%	10.34%
Earnings before Tax (EBT) ¹	1,883	901	3,575	6,163	5,357	9,862	6,776	7,576
Net income ¹	1,744	649	2,713	4,290	4,238	7,545	5,111	5,329
Net margin	3.73%	1.24%	4.92%	7.58%	7.01%	12.01%	7.93%	7.96%
EPS ²	61.81	22.96	95.72	151.2	150.1	266.5	180.6	188.3
Free Cash Flow ¹	154	-2,550	5,437	2,185	2,075	2,980	5,522	3,648
FCF margin	0.33%	-4.85%	9.85%	3.86%	3.43%	4.71%	8.56%	5.45%
FCF Conversion (EBITDA)	3.6%	-	78.63%	16.03%	25.2%	33.17%	58.13%	37.84%
FCF Conversion (Net income)	8.83%	-	200.41%	50.93%	48.96%	46.09%	108.04%	68.46%
Dividend per Share ²	14.00	17.00	14.00	15.00	16.00	40.00	50.00	48.33
Announcement Date	10/05/19	12/05/20	11/05/21	12/05/22	11/05/23	10/05/24	-	-

¹JPY in Million²JPY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March	2020 S1	2021 S1	2022 Q2	2022 S1	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 S1	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 S1	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 S1	2025 Q3	2025 Q4
Net sales ¹	26,582	27,403	14,256	28,477	15,702	12,428	15,269	14,903	30,172	17,087	13,202	16,023	15,625	31,648	17,176	14,019	16,284	15,677	32,616	17,430	13,870
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	746	1,946	1,469	2,657	2,020	118	1,664	1,215	2,879	2,162	67	1,704	1,351	3,055	2,471	974	1,832	1,500	3,462	2,690	840
Operating Margin	2.81%	7.1%	10.3%	9.33%	12.86%	0.95%	10.9%	8.15%	9.54%	12.65%	0.51%	10.63%	8.65%	9.65%	14.39%	6.95%	11.25%	9.57%	10.61%	15.43%	6.06%
Earnings before Tax (EBT)	918	1,952	-	-4,139	9,988	-	1,805	1,214	3,019	2,348	-	1,873	-	5,410	3,110	-	-	-	-	-	-
Net income ¹	577	1,552	-3,894	-2,796	6,878	208	1,323	1,023	2,346	1,837	55	1,428	2,701	4,129	2,329	1,087	1,394	1,140	2,635	2,044	668
Net margin	2.17%	5.66%	-27.31%	-9.82%	43.8%	1.67%	8.66%	6.86%	7.78%	10.75%	0.42%	8.91%	17.29%	13.05%	13.56%	7.75%	8.56%	7.27%	8.08%	11.73%	4.82%
EPS	20.42	54.77	-	-98.52	242.3	-	46.94	-	83.18	65.01	-	50.51	-	145.9	82.20	-	43.80	-	89.50	-	-
Dividend per Share	7.000	7.000	-	7.000	-	-	-	-	8.000	-	-	-	-	20.00	-	-	-	-	-	-	-
Announcement Date	05/11/19	04/11/20	01/11/21	01/11/21	07/02/22	12/05/22	08/08/22	07/11/22	07/11/22	06/02/23	11/05/23	07/08/23	06/11/23	06/11/23	05/02/24	10/05/24	-	-	-	-	-

¹JPY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: March	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	5,486	9,125	5,881	-	-	-	-	-
Net Cash position ¹	-	-	-	3,057	5,282	16,351	12,308	17,190
Leverage (Debt/EBITDA)	1.284 x	1.732 x	0.8505 x	-	-	-	-	-
Free Cash Flow ¹	154	-2,550	5,437	2,185	2,075	2,980	5,522	3,649
ROE (net income / shareholders' equity)	4.1%	1.5%	6.3%	8.8%	8.2%	13%	8.15%	8.03%
ROA (Net income/ Total Assets)	2.67%	2.11%	2.77%	5.17%	6.14%	7.33%	7.4%	8%
Assets ¹	65,369	30,734	97,942	82,940	69,028	102,892	69,068	66,613
Book Value Per Share ²	1,539	1,468	1,569	1,735	1,928	2,186	2,287	2,440
Cash Flow per Share ²	155.0	156.0	212.0	253.0	261.0	361.0	261.0	275.0
Capex ¹	2,350	2,058	1,104	657	1,276	981	1,000	1,981
Capex / Sales	5.03%	3.92%	2%	1.16%	2.11%	1.55%	1.55%	2.96%
Announcement Date	10/05/19	12/05/20	11/05/21	12/05/22	11/05/23	10/05/24	-	-

¹JPY in Million²JPY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ASKA Pharmaceutical Holdings Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,302 JPY

Average target price

2,733 JPY

Spread / Average Target

+18.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASKA PHARMACEUTICAL HOLDINGS CO.,LTD.	+29.04%	428M
ELI LILLY AND COMPANY	+33.01%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.82%	367B
MERCK & CO., INC.	+20.22%	334B
ABBVIE INC.	+5.94%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.10%	171B

Other Pharmaceuticals